Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Ascitic Drain Insertion And Management in Gynaecology (1077)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Ascitic Drain Insertion And Management in Gynaecology (1077)

Warning

Objectives

To describe the indications, procedure and monitoring required for the safe insertion of Ascitic Drains in gynaecology including post insertion monitoring

Scope

Women attending with Ascites to Gynaecology where management with Paracentesis Drain is considered

Audience

All healthcare professionals involved in the care of women with ascites who require insertion of Ascitic drain in the gynaecology setting

Please report any inaccuracies or issues with this guideline using our online form

Malignant ascites is the accumulation of fluid within the peritoneal cavity of the abdomen secondary to cancer (an exudate not a transudate). Within gynaecology, ascites is most commonly associated with those suffering with ovarian malignancy. Approximately 60% of patients with advanced ovarian cancer develop ascites necessitating hospital admission and treatment.

The symptoms associated with ascites can be distressing for the patient including abdominal distension and pain, breathlessness, nausea, vomiting, early satiety, constipation and peripheral oedema.  These can greatly impact on patients’ quality of life. 

The principle for management of malignant ascites should be aimed at symptomatic relief and improvement of quality of life. For most patients, paracentesis is the treatment of choice and relieves symptoms in up to 90% patients. It is most likely to relieve symptoms of abdominal distension/discomfort and dyspnoea, however less likely to improve the associated symptoms of peripheral oedema, fatigue and poor mobility.

Paracentesis is a simple procedure to remove ascitic fluid from the abdominal cavity, which can be performed as a day case or as an inpatient. Removal of 4–6 litres is usually enough to give symptomatic relief. Removal of more than 4-6 litres increases the risk of hypovolemia and adverse effects, but may give symptomatic relief for longer until the ascites re-accumulates.   

Paracentesis may not be appropriate if the prognosis is very short and the patient is rapidly deteriorating. 

Indications for drainage of ascites by abdominal paracentesis

  1. As a diagnostic procedure to determine the cause of ascites and ascertain cytological diagnosis. It should be kept in mind there are other causes of ascites other than malignancy. It can be helpful to also send ascites to microbiology and biochemistry. It can be useful to have a serum to-ascites Albumin Gradient (SAAG) if the ascites turns out not to be malignant.
  2. As a therapeutic procedure: in patients with large volume ascites to provide symptomatic relief.

Contraindications

  • Severe bowel distension
  • Severe coagulopathy
  • Disseminated intravascular coagulation
  • Local or systemic infection
  • Low white cell count / neutropenia
  • Skin infection at the proposed puncture site 
  • Distressed/uncooperative patient

Risks with Paracentesis

The risk associated with paracentesis can be associated with the removal of large volumes (> 6 litres) as this can cause a ‘fluid shift’ with resultant hypovolaemia and hypotension, leading to symptoms of dizziness, fatigue and malaise. Additional procedural risks include; perforation of abdominal viscus, haemorrhage, infection, discomfort. See appendix 1 for risks to be discussed with patient when consenting for procedure.

Ultrasound imaging (USS)

Drain insertion should be performed under ultrasound guidance or following marking.  Care should be taken particularly if ascitic fluid is not easily clinically identified, there has been difficulty with previous paracentesis, there is suspected loculation of ascites or there are concerns about bowel obstruction.  Consideration should be given to assistance from radiology department where difficulty is anticipated.

Pre-procedure

  • Review up to date FBC, coag, U+Es and LFTs
  • Check IV access sited and patent
  • Ensure site has been marked if USS guidance not available
  • Ensure nursing staff available to assist insertion
  • Obtain informed consent
  • Patient should empty bladder prior to procedure
  • Check full set of observations including – pulse, BP, temperature, respiratory rate and O2 saturations
  • Ensure correct equipment available – see appendix 2 for required equipment

Procedure

  • Place patient in semi upright position
  • Confirm the presence of ascites
  • The usual site for paracentesis is the left side but can be in either iliac fossa at least 10cm from midline or suprapubically (must ensure bladder is empty). The chosen site should avoid: distended bowel or bladder and inferior epigastric arteries. Guided by ultrasound marking if trained.

  • Abdomen is prepared with aseptic solution and sterile drape applied
  • Infiltrate up to 10ml of 2% lidocaine into the area to be cannulated.
  • Using local anaesthetic syringe, needle is inserted through sheath and ascites withdrawn. A larger needle may need to be considered in patients with a high BMI
  • When anaesthesia of insertion site achieved small incision made with scalpel and drain needle inserted. Once flashback is visualised, advance the catheter whilst withdrawing the needle.
  • If cytology required minimum 200ml should be sent
  • It can be useful to consider sending fluid to microbiology and biochemistry, particularly where the ascites turns out not to be malignant. Tests should include  Cell count and differential, Bacterial culture, Albumin (for serum-to-ascites albumin gradient (SAAG)), Total protein, Glucose and LDH.
  • Closed drainage system is attached.
  • If drain is to remain in situ sutures are inserted and sterile dressing applied.
  • Document the procedure, plan for drainage and required frequency of observation in the notes.
  • Record full set of observations again and volume drained immediately post procedure

Post insertion management of paracentesis drain

  • Record BP, pulse and temperature every 15 minutes for the first hour after insertion, hourly for 4hrs and 4 hourly thereafter if within normal limits
  • Monitor fluid balance and urea and electrolytes daily Observe paracentesis insertion site and change dressing daily.
  • If the patient becomes unwell, clamp the drain, take pulse, blood pressure and temperature and seek medical advice.
  • Aim to remove drain after 48hrs. If continuing to drain significant volumes discuss with medical staff regarding timing of removal

Drainage rate and amount

Most patients will tolerate the procedure well. Total amount drained will depend on the individual patient, the volume of ascites and previous experiences with paracentesis. 

Patient group

Rate

Fluids

Systolic BP >100

No relevant co-morbidites

Drain 1L every 2-4hrs

Max 6L in 24hrs

Not usually required

Systolic BP <100 prior to or during drainage

Cardiovascular or renal comorbidities (at medical staff instruction)

Drain 1L every 4hrs

Max 6L in 24hrs

If BP drops significantly or symptoms of hypovolaemia* - stop drainage and seek medical advice

Consider fluid replacement with IV crystalloid

*Signs and symptoms of hypovolaemia: high pulse, low BP; dizziness; increasing fatigue and malaise.

The drain should be clamped after each litre drained and removed once minimal volumes draining. If significant volumes still draining at 48hrs discuss with senior medical staff regarding keeping the drain in situ for ongoing drainage, this should be reviewed by a senior clinician every 24hrs.

For patients where chemotherapy is unlikely to be effective and who require repeated drainage, an indwelling catheter should be considered and should be discussed with the oncology team.

Editorial Information

Last reviewed: 23/03/2023

Next review date: 31/03/2028

Author(s): Dr Morton Hair, Consultant Gynaecologist.

Version: 1

Approved By: Gynaecology Clinical Governance Group

Document Id: 1077